Efficacy endpoints
The main study variable was to evaluate changes in viral load from baseline to day 4 and was observed similar in the domperidone and placebo groups for the three SARS-CoV-2 genes, ORF1ab, N Protein and S Protein (Evolution of Ct values of ORF1ab, N Protein and S Protein at follow-up in the two study groups.Ct values of ORF1ab, N Protein and S Protein increased significantly from baseline to days 4 and 14 (No significant differences were observed between the main analysis and the sensitivity analysis results.No significant differences were found between domperidone and placebo in the proportion of patients with RT-qPCR positive on day 4 (92% vs. 89.5%, Kaplan–Meier curves for the median time to obtain an RT-qPCR negative result by study group.The vital signs significantly improved from day 1 to day 28 (Persistent symptoms observed after 28 days of follow-up by study groups.%: Percentage of persistent symptoms in each group.